Understanding how gut bacteria changes may influence lung cancer development.
Dissecting the role of gut microbiome dysbiosis in lung cancer development and progression.
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-11066881
This study is looking at how changes in gut bacteria might be linked to lung cancer, especially in people who have smoked, and it hopes to find new ways to help prevent and treat this type of cancer.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11066881 on ClinicalTrials.gov |
What this research studies
This research investigates the connection between gut microbiome changes and the development of lung adenocarcinoma, the most common type of lung cancer. It focuses on how alterations in gut bacteria can lead to systemic inflammation that may promote tumor growth, particularly in individuals with a history of tobacco use. By studying mouse models that mimic human conditions, the research aims to uncover the mechanisms by which gut microbiome dysbiosis affects lung cancer progression. The findings could lead to new strategies for prevention and treatment in high-risk populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of tobacco use who are at high risk for developing lung adenocarcinoma.
Not a fit: Patients who do not have a history of tobacco use or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide insights into new preventive measures or treatments for lung cancer, particularly for individuals at high risk.
How similar studies have performed: Previous studies have shown promising results in understanding the role of gut microbiome in cancer development, suggesting that this approach may yield valuable insights.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIU, YUEJIANG — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: LIU, YUEJIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.